ArticlePloS one2014
The potential biomarker panels for identification of Major Depressive Disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomics in Depression: What We Learn from Preclinical and Clinical Evidences.Molecular neurobiology · 2025Pooled it
- Towards Objective Major Depressive Disorder Detection: a Systematic Review and Meta-Analysis of Diagnostic Biomarkers.The Psychiatric quarterly · 2025Review
- Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects.Journal of psychopharmacology (Oxford, England) · 2025Article
- Using an Interpretable Amino Acid-Based Machine Learning Method to Enhance the Diagnosis of Major Depressive Disorder.Journal of clinical medicine · 2024Article
- Plasma amino acids in major depressive disorder: between pathology to pharmacology.EXCLI journal · 2024Review
- Association of serum oleic acid level with depression in American adults: a cross-sectional study.BMC psychiatry · 2023Article
- Metabolic Fingerprints of Effective Fluoxetine Treatment in the Prefrontal Cortex of Chronically Socially Isolated Rats: Marker Candidates and Predictive Metabolites.International journal of molecular sciences · 2023Article
- Review
- Breathomics profiling of metabolic pathways affected by major depression: Possibilities and limitations.Frontiers in psychiatry · 2022Article
- Discovery and validation of acetyl-L-carnitine in serum for diagnosis of major depressive disorder and remission status through metabolomic approach.Frontiers in psychiatry · 2022Article
- Effect of Coriander Plants on Human Emotions, Brain Electrophysiology, and Salivary Secretion.Biology · 2021Article
- Metabolomics-based discrimination of patients with remitted depression from healthy controls usingScientific reports · 2021Article
- Review
- Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice.The American journal of psychiatry · 2020Article
- Metabonomic Profile and Signaling Pathway Prediction of Depression-Associated Suicidal Behavior.Frontiers in psychiatry · 2020Article
- Examining the Influence of Early Life Stress on Serum Lipid Profiles and Cognitive Functioning in Depressed Patients.Frontiers in psychology · 2019Article
- Serum profile changes in postpartum women with a history of childhood maltreatment: a combined metabolite and lipid fingerprinting study.Scientific reports · 2018Article
- Blood plasma/IgG N-glycome biosignatures associated with major depressive disorder symptom severity and the antidepressant response.Scientific reports · 2018Article
- Blood and urinary metabolomic evidence validating traditional Chinese medicine diagnostic classification of major depressive disorder.Chinese medicine · 2018Article
- Social defeat stress causes depression-like behavior with metabolite changes in the prefrontal cortex of rats.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe lack of the disease biomarker to support objective laboratory tests still constitutes a bottleneck in the clinical diagnosis and evaluation of major depressive disorder (MDD) and its subtypes. We used metabonomic techniques to screen the diagnostic biomarker panels from the plasma of MDD patients with and without early life stress (ELS) experience.
methodsPlasma samples were collected from 25 healthy adults and 46 patients with MDD, including 23 patients with ELS and 23 patients without ELS. Furthermore, gas chromatography/mass spectrometry (GC/MS) coupled with multivariate statistical analysis was used to identify the differences in global plasma metabolites among the 3 groups.
resultsThe distinctive metabolic profiles exist either between healthy subjects and MDD patients or between the MDD patients with ELS experience (ELS/MDD patients) and the MDD patients without it (non-ELS/MDD patients), and some diagnostic panels of feature metabolites' combination have higher predictive potential than the diagnostic panels of differential metabolites.
conclusionsThese findings in this study have high potential of being used as novel laboratory diagnostic tool for MDD patients and it with ELS or not in clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.